Familial amyloid polyneuropathy: New developments in genetics and treatment

Current Opinion in Neurology

Volumn 9, Issue 5, 1996, Pages 355-359

  Coelho, Teresa ^a  

^a HOSPITAL DE SANTO ANTÓNIO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; PREALBUMIN;

AMYLOID NEUROPATHY; AMYLOIDOSIS; DISEASE COURSE; FATALITY; GENE MUTATION; HUMAN; LIVER; LIVER TRANSPLANTATION; PERIPHERAL NEUROPATHY; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SHORT SURVEY;

EID: 0029859731     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199610000-00007     Document Type: Short Survey

References (66)

1. Van Allen MW, Frohlich JA, Davis JR: Inherited predisposition to generalized amyloidosis: clinical and pathological study of a family with neuropathy, nephropathy and peptic ulcer. Neurology 1969, 19:10-25.
2. Meretoja J: Familial systemic paramyloidosis with lattice dystrophy of the cornea, progressive cranial neuropathy, skin changes and various internal symptoms. Ann Clin Res 1969, 1:314-324.
3. de la Chappelle A, Tolvanen R, Boysen G, Santavy J, Bleeker-Wagemakers L, Maury GPJ, Kere J: Gelsolin-derived familial amyloidosis caused by asparagine or tyrosine substitution for aspartic acid at residue 187. Nature Genet 1992, 2:157-160.
4. Boysen G, Galassi G, Kamieniecka Z, Schlaeger J, Trojaborg W: Familial amyloidosis with cranial neuropathy and comeal lattice dystrophy. J Neurol Neurosurg Psychiatry 1979, 42:1020-1030.
5. Sunada Y, Shimizu T, Nakase H, Ohta S, Asaoka T, Amano S, Sawa M, Kagawa Y, Kanasawa I, Mannen T: Inherited amyloid polyneuropathy type IV (gelsolin variant) in a Japanese family. Ann Neurol 1993, 33:57-62.
6. Paunio T, Sunada Y, Kiuru S, Makishita H, Ikeda S, Weissenbach J, Palo J, Peltonen L: Haplotype analysis in gelsolin-related amyloidosis reveals Independent origin of identical mutation (G654A) of gelsolin in Finland and Japan. Hum Mutat 1995, 6:60-65.
7. Murakami T, Uchino M, Ando M: Genetic abnormalities and pathogenesis • of familial amyloidotic polyneuropathy. Pathol Int 1995, 45:1-9. A clear and accessible review of basic aspects of investigations into FAP.
8. Uemichi T, Gertz MA, Benson MD: A new transthyretin variant (Ser24) associated with familial amyloid polyneuropathy. J Med Genet 1995, 32:279-281.
9. Jenne DE, Denzel K, Blätzinger P, Obermaier-Skrobaneck B, Linke RP, Altland K: A highly conservative IIe20 substitution at the dimer-dimer interface selectively reduces stability of the tetrameric transthyretin complex and is associated with familial cardiomyopathy [Abstract]. Neuromusc Disord 1996, 6(suppl 1):17.
10. Jacobson DR, Kyle RA, Buxbaum JN: TTR IIe20, a new variant associated with cardiac amyloidosis [Abstract]. Neuromusc Disord 1996, 6(suppl 1):18.
11. Booth DR, Booth SE, Persey MR, Tan SY, Madhoo S, Pepys MB, Hawkins PN: Three new amyloidogenic TTR mutations: Pro12, Glu18 and Val33 [Abstract]. Neuromusc Disord 1996, 6(suppl 1):20.
12. Uemichi T, Liepnieks JJ, Waits RP, Benson MD: In frame deletion in the transthyretin gene (D V122) associated with amyloidotic polyneuropathy [Abstract] Neuromusc Disord 1996, 6(suppl 1):21.
13. Alves IL, Altland K, Almeida MR, Winter P, Saraiva MJM: Screening and biochemical characterisation of transthyretin variants in the Portuguese population. Hum Mutat 1996 (In press).
14. Jacobson DR, Alves IL, Saraiva MJM, Thibodeau SN, Buxbaum JN: Transthyretin Ser6 gene frequency in Individuals without amyloidosis. Hum Genet 1995, 95:308-312.
15. Saraiva MJM: Transthyretin mutations In health and disease. Hum Mutat 1995, 5:191-196.
16. Jacobson DR, Buxbaum JN: A double-variant transthyretin allele (Ser6, IIe33) in the Israeli patient 'SKO' with familial amyloidotic polyneuropathy. Hum Mutat 1994, 3:254-260.
17. Skare J, Jones LA, Myles N, Kane K, Milunsky A, Cohen A, Skinner M: Two transthyretin mutations (glu42gly, his90asn) in an Italian family with amyloidosis. Clin Genet 1994, 45:281-284.
18. Nordvȧg BY, Ranløv I, El-Gewely MR, Husby G: Two transthyretin variants, Ser6 and Met111, In a Danish kindred with familial amyloid cardiomyopathy: implications for serum TTR and thyroxine hormone levels. Int J Exp Clin Invest 1995, 2:241-250.
19. Coelho T, Chorāo R, Sousa A, Alves I, Torres MF, Saraiva MJM: Compound heterozygotes of transthyretin Met30 and transthyretin Met119 are protected from the devastating effects of familial amyloid polyneuropathy [Abstract] Neuromusc Disord 1996, 6(suppl 1):20.
20. Alves IL, Saraiva MJM: Comparative catabolism and stability of TTR Met30 and TTR Met119 [Abstract]. Neuromusc Disord 1996, 6(suppl 1):19.
21. Ioshioka K, Furuya H, Sasaki H, Saraiva MJM, Costa PP, Sakaki Y: Haplotype analysis of familial amyloidotic polyneuropathy. Hum Genet 1989, 82:9-13.
22. Waits RP, Uemichi T, Benson MD: Haplotype analysis of the transthyretin gene: evidence for multiple recurrence of the Met30 mutation in the Caucasian population. Int J Exp Clin Invest 1995, 2:114-118.
23. Reilly MM, Adams D, Davis MB, Said G, Harding AE. Haplotype analysis of French, British and other European patients with familial amyloid polyneuropathy (Met30 and Tyr77). J Neurol 1995, 242:664-668.
24. Almeida MR, Aoyama-Oishi N, Sakaki Y, Holmgren G, Drugge U, Ferlini A, Salvi F, Munar-Qués M, Benson MD, Skinner M et al.: Haplotype analysis of common transthyretin mutations. Hum Genet 1995, 96:350-354
25. Sousa A, Coelho T, Barros J, Sequeiros J: Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type 1 in Póvoa do Varzim and Vila do Conde (North of Portugal). Am J Med Genet 1995, 60:512-521.
26. Sousa A, Andersson R, Drugge U, Holmgren G, Sandgren O: Familial amyloidotic polyneuropathy in Sweden: geographical distribution, age of onset and prevalence. Hum Hered 1993, 43:288-294.
27. Holmgren G, Costa PM, Andersson C, Asplund K, Steen L, Beckman L, Nylander PO, Teixeira A, Saraiva MJM, Costa PP: Geographical distribution of TTR Met30 carriers In northern Sweden: discrepancy between carrier frequency and prevalence rate. J Med Genet 1994, 31:351-354.
28. Reilly MM, Staunton H, Harding AE: Familial amyloid polyneuropathy (TTR • Ala60) in north-west Ireland: a clinical, genetic, and epidemiological study. J Neurol Neurosurg Psychiatry 1995, 59:45-49. A global approach to a disease that occurs more frequently than previously thought.
29. Buxbaum JN, Yergubian R, Gallo G, Buck F, Jacobson DR: Molecular genetics of transthyretin-associated senile cardiac amyloidosis in blacks [Abstract]. Neuromusc Disord 1996, 6(suppl 1):22.
30. Saunders AM, Strittmatter WJ, Schmechel D, St. George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ et al. Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993, 43: 1467-1472.
31. Saunders AM, Schmader K, Breitner JCS, Benson MD, Brown WT, Goldfarb D, Manwaring MG, Szymanski MH, McCown N, Dole KC et al.: Apolipoprotein E ε4 allele distributions In late-onset Alzheimer's disease and other amyloid-forming diseases. Lancet 1993, 342:710-711.
32. Lovat LB, Booth SE, Booth DR, Madhoo S, Holmgren G, Hawkins PN, Soutar AK, Pepys MB: Apolipoprotein E ε4 genotype is not a risk factor for systemic AA amyloidosis or familial amyloid polyneuropathy. Int J Exp Clin Invest 1995, 2:163-166.
33. Coelho T, Sousa A, Lourenço E, Ramalheira J: A study of 159 Portuguese patients with familial amyloidotic polyneuropathy (FAP) whose parents were both unaffected. J Med Genet 1994, 31:293-299.
34. Li S, Sommer S: The high frequency of TTR Met30 in familial amyloidotic polyneuropathy is not due to a founder effect Hum Mol Genet 1993, 2:1303-1305.
35. Sousa A, Coelho T, Lobato L, Sequeiros J: Parental transmission and anticipation of age-of-onset in FAP-I. Am J Hum Genet 1991, 49:483.
36. Sousa A, Coelho T, Lobato L, Barros J, Sequeiros J: Anticipation in familial amyloid neuropathy type 1 (FAP-1) [Abstract]. J Neurol 1995, 242(suppl 2):148.
37. Drugge U, Andersson R, Chizari F, Danielsson M, Holmgren G, Sandgren O, Sousa A: Familial amyloidotic polyneuropathy In Sweden: a pedigree analysis. J Med Genet 1993, 30:388-392.
38. Yamamoto K, Ikeda S, Hanyu N, Yanagisawa N: Anticipation and multiple origins in familial amyloid polyneuropathy with transthyretln-Met30 in Japan [Abstract]. Neuromusc Disord 1996, 6(suppl 1):42.
39. Barros J, Coelho T, Lobato L, Sousa A: Unusual phenotypic variability within the same family: variable penetrance and variable clinical expression [Abstract]. Neuromusc Disord 1996, 6(suppl 1):39.
40. Lobato L, Beirǎo I, Monteiro P, Saraiva MJM, Coelho T, Sousa A: Epidemiology and genetic analysis in patients with familial amyloid polyneuropathy (FAP) type 1 and end-stage renal disease: can we predict kidney Involvement? [Abstract]. Neuromusc Disord 1996, 6(suppl 1):51.
41. Fiori MG, Salvi F, Plasmati R, Tessari F, Bianchi R, Tassinari CA: Amyloid deposits inside myocardial fibers in transthyretin-Met30 familial amyloidotic polyneuropathy. A histological and biochemical study. Cardiology 1994, 85:145-153.
42. Reilly MM, Adams D, Booth DR, Davis MB, Said G, Laubriat-Bianchin M, Pepys MB, Thomas PK, Harding AE: Transthyretin gene analysis In European patients with suspected familial amyloid polyneuropathy. Brain 1995, 118:849-856.
43. Torres MF, Almeida MR Saraiva MJM: TTR exon scanning in peripheral neuropathies. Neuromusc Disord 1995, 5:187-191.
44. Ando Y, Obayashi K, Tanaka Y, Yamashita T, Uchino M, Ando M: A new and sensitive tool for autonomic dysfunction: analysis by radiolabelled meta-iodobenzylguanidine (MIBG) in patients with familial amyloidotic polyneuropathy (FAP). Int J Exp Clin Invest 1995, 2:183-187.
45. Olofsson B-O, Suhr O, Niklasson U, Wiklund U, Bjerle P, Beckman A: Assessment of autonomic nerve function in familial amyloidotic polyneuropathy: a clinical study based on spectral analysis of heart rate variability. Int J Exp Clin Invest 1994, 1:240-246.
46. Yonehara T, Ando Y, Kimura K, Uchino M, Ando M: Detection of reverse flow by duplex ultrasonography in orthostatic hypotension. Stroke 1994, 25:2407-2411.
47. Suhr O, Danielsson A, Holmgren G, Steen L: Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy. J Intern Med 1994, 235:479-485.
48. Ando Y, Gotoh T, Kawaguchi Y, Tanaka Y, Sakashita N, Ando M: Intranasal L-threo-3,4,-dihydroxyphenylserine in treating diarrhea associated with familial amyloidotic polyneuropathy. Pharmacotherapy 1995, 15:345-349.
49. Tan SY, Pepys MB, Hawkins PN: Treatment of amyloidosis. Am J Kidney Dis • 1995, 26:267-285. An extensive review of the therapies available for treatment of amyloidosis.
50. Steen L, Holmgren G, Suhr O, Wikström L, Groth C-G, Ericzon B-G: Worldwide survey of liver transplantation in patients with familial amyloidotic polyneuropathy. Int J Exp Clin Invest 1994, 1:138-142.
51. Ericzon B-G: Liver transplantation for familial amyloid polyneuropathy - report from the world register [Abstract]. Neuromusc Disord 1996, 6(suppl 1):65.
52. Ericzon B-G, Suhr O, Broome U, Holmgren G, Duraj F, Eleborg L, •• Wikström L, Norden G, Friman S, Groth C-G: Liver transplantation halts the progress of familial amyloidotic polyneuropathy. Transplant Proc 1995, 27:1233. A report on the effects of liver transplantation from the group that pioneered this procedure for FAP patients.
53. Parrilla P, Ramirez P, Bueno FS, Robles R, Acosta F, Miras M, Pons JA, •• Andreu FL, Munar-Qués M: Clinical Improvement after liver transplantation for type I familial amyloid polyneuropathy. Br J Surg 1995, 82:825-828. A detailed analysis of the Spanish experience of using liver transplantation to treat FAP.
54. Lewis WD, Skinner M, Simms RW, Jones LA, Cohen AS, Jenkins RL: Orthotopic liver transplantation for familial amyloidotic polyneuropathy. Clin Transplant 1994, 8:107-110.
55. Adams D, Samuel D, Goulon-Goeau C, Costa PMP, Nakazato M, Bismuth H, Said G: Evaluation of liver transplantation In familial amyloid polyneuropathy [Abstract]. Neuromusc Disord 1996, 6(suppl 1):76.
56. Hawkins PN, Persey MR, Lovai LB, Madhoo S, Stangou A, McCarthy M, Heaton N, Williams R, Pepys MB: UK experience of liver transplantation in FAP [Abstract]. Neuromusc Disord 1996, 6(suppl 1):77.
57. Monteiro E, Morbey A, Freire A, Veloso A, Rebelo-Andrade J, Barroso E, Salles-Luis ML, Costa PP, Pena J: Is orthotopic liver transplantation (OLTx) a good therapy for familial amyloid polyneuropathy? Lisbon experience [Abstract]. Neuromusc Disord 1996, 6(suppl 1):80.
58. Cruz MW, Novis SAP, Raia S: Liver transplantation in FAP type 1 Brazilian patients [Abstract]. Neuromusc Disord 1996, 6(suppl 1):82.
59. Tzagournissakis M, Kostopanagiotou G, Papadimitriou J: Liver transplantation for familial amyloidotic polyneuropathy in Greece [Abstract]. Neuromusc Disord 1996, 6(suppl 1):84.
60. Matsunami H, Makuuchi M, Kawasaki S, Hashikura Y, Ikegami T, Nakazawa Y, • Miyagawa S, Takei Y, Ikeda S, Yanagisawa N: A case of familial amyloid polyneuropathy treated with partial liver transplantation using a graft from a living related donor. Transplantation 1995, 60:301-303. A report of a case in which transplantation was performed using a living donor.
61. Lewis WD, Skinner M: Liver transplantation for familial amyloidotic polyneuropathy: a potential curative treatment [Editorial], Int J Exp Clin Invest 1994, 1:143-144.
62. Suhr OB, Holmgren G, Steen L, Wikström L, Norden G, Friman S, Duraj FF, •• Groth C-G, Ericzon B-G: Liver transplantation in familial amyloidotic polyneuropathy. Follow-up of the first 20 Swedish patients. Transplantation 1995, 60:933-938 An important assessment of the factors that influence the outcome of liver transplantation in FAP patients.
63. Homgren G, Steen L, Ekstedt J, Groth CG, Ericzon BG, Enksson S, Anderson O, Karlberg I, Norden G, Nakazato M et al.: Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic neuropathy (FAP-met30). Clin Genet 1991, 40:242-246.
64. Skinner M, Lewis D, Jones LA, Kasirsky J, Kane K, Ju ST, Jenkins R, Falk RH, Simms RW, Cohen AS: Liver transplantation as a treatment for familial amyloidotic polyneuropathy. Ann Intern Med 1994, 120:133-134.
65. Larue JR, Samuel D, Adams D, Meduri G, Hiesse C, Said G, Charpentier B, Bismuth H : Renal involvement In amyloid polyneuropathy. Implications for pre-liver transplantation evaluation [Abstract]. Neuromusc Disord 1996, 6(suppl 1):67.
66. Ando Y, Tanaka Y, Nakazato M, Ericzon B-G, Yamashita T, Tashima K, •• Sakashita N, Suga M, Uchino M, Ando M: Change in variant transthyretin levels In patients with familial amyloidotic polyneuropathy type I following liver transplantation. Biochem Biophys Res Commun 1995, 211: 354-358. A detailed analysis of variant transthyretin levels in blood and cerebrospinal fluid after liver transplantation.